CardioGenerics will develop key physician partners in the midwest; Michigan, Minnesota and Illinois. These hospitals will evaluate the product prior to launch to validate that the product meets the customer needs. (Note: safety and efficacy testing will be done prior to customer validation)
CardioGenerics will exhibit at 8-10 major cardiac surgery meetings in the U.S., Europe and Asia Pacific. During the second year, we will hire three direct sales representatives and at least one European distributor.
Full product launch should happen 12 months after receiving seed funding.